On day 7, the % of intratumoral CD8+ T cells was 2-fold higher in the mmHERA-CD40L treated mice, correlating with clearly decreased tumor growth measured on day 7 onwards (Figure 5C).This was further highlighted upon IHC analysis of tumor sections. This evidence concerns the gene CD8A and neoplasm.